Table of Contents Author Guidelines Submit a Manuscript
International Journal of Inflammation
Volume 2010, Article ID 151097, 18 pages
http://dx.doi.org/10.4061/2010/151097
Review Article

The Regulation of the CNS Innate Immune Response Is Vital for the Restoration of Tissue Homeostasis (Repair) after Acute Brain Injury: A Brief Review

1Deptartment of Medical Biochemistry, University Hospital of Wales, Cardiff University Medical School, Cardiff CF14 4XN, UK
2University Labo. Biochimie et Genetique Moleculaire, Facilities de Science et Technologies, Universite de La Reunion, 15 Avenue Rene Cassin Saint Denis, Ile de la Reunion, BP 7151, 97715, France
3Deptartment of Histopathology, University Hospital of Wales, Cardiff University Medical School, Cardiff CF14 4XN, UK

Received 3 August 2009; Revised 6 January 2010; Accepted 28 April 2010

Academic Editor: Cai Song

Copyright © 2010 M. R. Griffiths et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. M. Friedlander, “Apoptosis and caspases in neurodegenerative diseases,” The New England Journal of Medicine, vol. 348, no. 14, pp. 1365–1375, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. T. Sairanen, M.-L. Karjalainen-Lindsberg, A. Paetau, P. Ijäs, and P. J. Lindsberg, “Apoptosis dominant in the periinfarct area of human ischaemic stroke—a possible target of antiapoptotic treatments,” Brain, vol. 129, no. 1, pp. 189–199, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. M. D. Nguyen, J.-P. Julien, and S. Rivest, “Innate immunity: the missing link in neuroprotection and neurodegeneration?” Nature Reviews Neuroscience, vol. 3, no. 3, pp. 216–227, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. M. Hauwel, E. Furon, C. Canova, M. Griffiths, J. Neal, and P. Gasque, “Innate (inherent) control of brain infection, brain inflammation and brain repair: the role of microglia, astrocytes, “protective” glial stem cells and stromal ependymal cells,” Brain Research Reviews, vol. 48, no. 2, pp. 220–233, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. C. N. Serhan, S. D. Brain, and S. D. Brain, “Resolution of inflammation: state of the art, definitions and terms,” The FASEB Journal, vol. 21, no. 2, pp. 325–332, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. P. G. Popovich and E. E. Longbrake, “Can the immune system be harnessed to repair the CNS?” Nature Reviews Neuroscience, vol. 9, no. 6, pp. 481–493, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. T. Wyss-Coray and L. Mucke, “Inflammation in neurodegenerative disease—a double-edged sword,” Neuron, vol. 35, no. 3, pp. 419–432, 2002. View at Publisher · View at Google Scholar · View at Scopus
  8. K. Elward and P. Gasque, “"Eat me" and "don't eat me" signals govern the innate immune response and tissue repair in the CNS: emphasis on the critical role of the complement system,” Molecular Immunology, vol. 40, no. 2–4, pp. 85–94, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. C. Grimsley and K. S. Ravichandran, “Cues for apoptotic cell engulfment: eat-me, don't eat-me and come-get-me signals,” Trends in Cell Biology, vol. 13, no. 12, pp. 648–656, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Griffiths, J. W. Neal, and P. Gasque, “Innate immunity and protective neuroinflammation: new emphasis on the role of neuroimmune regulatory proteins,” International Review of Neurobiology, vol. 82, pp. 29–55, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. M. R. Griffiths, P. Gasque, and J. W. Neal, “The multiple roles of the innate immune system in the regulation of apoptosis and inflammation in the brain,” Journal of Neuropathology and Experimental Neurology, vol. 68, no. 3, pp. 217–226, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. H. Neumann, “Control of glial immune function by neurons,” Glia, vol. 36, no. 2, pp. 191–199, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. J. Husemann, J. D. Loike, R. Anankov, M. Febbraio, and S. C. Silverstein, “Scavenger receptors in neurobiology and neuropathology: their role on microglia and other cells of the nervous system,” Glia, vol. 40, no. 2, pp. 195–205, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. R. Alarcón, C. Fuenzalida, M. Santibáñez, and R. Von Bernhardi, “Expression of scavenger receptors in glial cells: comparing the adhesion of astrocytes and microglia from neonatal rats to surface-bound β-amyloid,” Journal of Biological Chemistry, vol. 280, no. 34, pp. 30406–30415, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. T. Ben-Hur, “Immunomodulation by neural stem cells,” Journal of the Neurological Sciences, vol. 265, no. 1-2, pp. 102–104, 2008. View at Publisher · View at Google Scholar · View at PubMed
  16. A. Keating, “How do mesenchymal stromal cells suppress T cells?” Cell Stem Cell, vol. 2, no. 2, pp. 106–108, 2008. View at Publisher · View at Google Scholar · View at PubMed
  17. H. Ohtaki, J. H. Ylostalo, J. E. Foraker, A. P. Robinson, R. L. Reger, S. Shioda, and D. J. Prockop, “Stem/progenitor cells from bone marrow decrease neuronal death in global ischemia by modulation of inflammatory/immune responses,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 38, pp. 14638–14643, 2008. View at Publisher · View at Google Scholar · View at PubMed
  18. P. D. Stahl and R. A. B. Ezekowitz, “The mannose receptor is a pattern recognition receptor involved in host defense,” Current Opinion in Immunology, vol. 10, no. 1, pp. 50–55, 1998. View at Publisher · View at Google Scholar
  19. E. M. E. Burudi and A. Régnier-Vigouroux, “Regional and cellular expression of the mannose receptor in the post-natal developing mouse brain,” Cell and Tissue Research, vol. 303, no. 3, pp. 307–317, 2001. View at Publisher · View at Google Scholar
  20. E. M. E. Burudi, S. Riese, P. D. Stahl, and A. Regnier-Vigouroux, “Identification and functional characterisation of the mannose receptor in astrocytes,” Glia, vol. 25, pp. 44–55, 1999. View at Google Scholar
  21. N. Laflamme and S. Rivest, “Toll-like receptor 4: the missing link of the cerebral innate immune response triggered by circulating gram-negative bacterial cell wall components,” The FASEB Journal, vol. 15, no. 1, pp. 155–163, 2001. View at Publisher · View at Google Scholar · View at PubMed
  22. I. S. Coraci, J. Husemann, and J. Husemann, “CD36, a class B scavenger receptor, is expressed on microglia in Alzheimer's disease brains and can mediate production of reactive oxygen species in response to β-amyloid fibrils,” American Journal of Pathology, vol. 160, no. 1, pp. 101–112, 2002. View at Google Scholar
  23. C. D. Gregory, “CD14-dependent clearance of apoptotic cells: relevance to the immune system,” Current Opinion in Immunology, vol. 12, no. 1, pp. 27–34, 2000. View at Publisher · View at Google Scholar
  24. R. Medzhitov and C. Janeway Jr., “Innate immune recognition: mechanisms and pathways,” Immunological Reviews, vol. 173, pp. 89–97, 2000. View at Publisher · View at Google Scholar
  25. R. Medzhitov and C. A. Janeway Jr., “Innate immunity: the virtues of a nonclonal system of recognition,” Cell, vol. 91, no. 3, pp. 295–298, 1997. View at Publisher · View at Google Scholar
  26. S. Gordon, “Pattern recognition receptors: doubling up for the innate immune response,” Cell, vol. 111, no. 7, pp. 927–930, 2002. View at Publisher · View at Google Scholar
  27. J. Savill, I. Dransfield, C. Gregory, and C. Haslett, “A blast from the past: clearance of apoptotic cells regulates immune responses,” Nature Reviews Immunology, vol. 2, no. 12, pp. 965–975, 2002. View at Publisher · View at Google Scholar · View at PubMed
  28. C. D. Gregory and A. Devitt, “The macrophage and the apoptotic cell: an innate immune interaction viewed simplistically?” Immunology, vol. 113, no. 1, pp. 1–14, 2004. View at Publisher · View at Google Scholar · View at PubMed
  29. F. Reichert and S. Rotshenker, “Complement-receptor-3 and scavenger-receptor-AI/II mediated myelin phagocytosis in microglia and macrophages,” Neurobiology of Disease, vol. 12, no. 1, pp. 65–72, 2003. View at Publisher · View at Google Scholar
  30. K. Takahashi, C. D. P. Rochford, and H. Neumann, “Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells-2,” Journal of Experimental Medicine, vol. 201, no. 4, pp. 647–657, 2005. View at Publisher · View at Google Scholar · View at PubMed
  31. P. Gasque, J. W. Neal, S. K. Singhrao et al., “Roles of complement system in human Neurodegenerative disorders,” Molecular Neurobiology, vol. 23, pp. 189–205, 2001. View at Google Scholar
  32. P. Gasque, “Complement: a unique innate immune sensor for danger signals,” Molecular Immunology, vol. 41, no. 11, pp. 1089–1098, 2004. View at Publisher · View at Google Scholar · View at PubMed
  33. D. Mevorach, J. O. Mascarenhas, D. Gershov, and K. B. Elkon, “Complement-dependent clearance of apoptotic cells by human macrophages,” Journal of Experimental Medicine, vol. 188, no. 12, pp. 2313–2320, 1998. View at Publisher · View at Google Scholar
  34. P. Gasque, A. Ischenko, J. Legoedec, C. Mauger, M.-T. Schouft, and M. Fontaine, “Expression of the complement classical pathway by human glioma in culture. A model for complement expression by nerve cells,” Journal of Biological Chemistry, vol. 268, no. 33, pp. 25068–25074, 1993. View at Google Scholar
  35. G. J. Wright, M. Jones, M. J. Puklavec, M. H. Brown, and A. N. Barclay, “The unusual distribution of the neuronal/lymphoid cell surface CD200 (OX2) glycoprotein is conserved in humans,” Immunology, vol. 102, no. 2, pp. 173–179, 2001. View at Publisher · View at Google Scholar
  36. R. M. Hoek, S. R. Ruuls, C. A. Murphy et al., “Down-regulation of the macrophage lineage through interaction with OX2 (CD200),” Science, vol. 290, no. 5497, pp. 1768–1771, 2000. View at Publisher · View at Google Scholar
  37. N. Koning, L. Bö, R. M. Hoek, and I. Huitinga, “Downregulation of macrophage inhibitory molecules in multiple sclerosis lesions,” Annals of Neurology, vol. 62, no. 5, pp. 504–514, 2007. View at Publisher · View at Google Scholar · View at PubMed
  38. M. Webb and A. N. Barclay, “Localisation of the MRC OX-2 glycoprotein on the surfaces of neurones,” Journal of Neurochemistry, vol. 43, no. 4, pp. 1061–1067, 1984. View at Google Scholar
  39. E. J. Brown and W. A. Frazier, “Integrin-associated protein (CD47) and its ligands,” Trends in Cell Biology, vol. 11, no. 3, pp. 130–135, 2001. View at Publisher · View at Google Scholar
  40. A. N. Barclay, G. J. Wright, G. Brooke, and M. H. Brown, “CD200 and membrane protein interactions in the control of myeloid cells,” Trends in Immunology, vol. 23, no. 6, pp. 285–290, 2002. View at Publisher · View at Google Scholar
  41. J. S. Pachter, H. E. De Vries, and Z. Fabry, “The blood-brain barrier and its role in immune privilege in the central nervous system,” Journal of Neuropathology and Experimental Neurology, vol. 62, no. 6, pp. 593–604, 2003. View at Google Scholar
  42. C. Canova, J. W. Neal, and P. Gasque, “Expression of innate immune complement regulators on brain epithelial cells during human bacterial meningitis,” Journal of Neuroinflammation, vol. 3, p. 22, 2006. View at Publisher · View at Google Scholar · View at PubMed
  43. G. Martino, R. Furlan, G. Comi, and L. Adorini, “The ependymal route to the CNS: an emerging gene-therapy approach for MS,” Trends in Immunology, vol. 22, no. 9, pp. 483–490, 2001. View at Publisher · View at Google Scholar
  44. P. G. McMenamin, “Distribution and phenotype of dendritic cells and resident tissue macrophages in the dura mater, leptomeninges, and choroid plexus of the rat brain as demonstrated in wholemount preparations,” Journal of Comparative Neurology, vol. 405, no. 4, pp. 553–562, 1999. View at Google Scholar
  45. B. O. Fabriek, E. S. Van Haastert, and E. S. Van Haastert, “CD163-positive perivascular macrophages in the human CNS express molecules for antigen recognition and presentation,” Glia, vol. 51, no. 4, pp. 297–305, 2005. View at Publisher · View at Google Scholar · View at PubMed
  46. H. E. De Vries, J. J. A. Hendriks, and J. J. A. Hendriks, “Signal-regulatory protein α-CD47 interactions are required for the transmigration of monocytes across cerebral endothelium,” Journal of Immunology, vol. 168, no. 11, pp. 5832–5839, 2002. View at Google Scholar
  47. B. M. Pratt and J. M. McPherson, “TGF-β in the central nervous system: potential roles in ischemic injury and neurodegenerative diseases,” Cytokine and Growth Factor Reviews, vol. 8, no. 4, pp. 267–292, 1997. View at Publisher · View at Google Scholar
  48. S. R. Barnum and J. L. Jones, “Transforming growth factor-β1 inhibits inflammatory cytokine-induced C3 gene expression in astrocytes,” Journal of Immunology, vol. 152, no. 2, pp. 765–773, 1994. View at Google Scholar
  49. J. M. Weiss, S. A. Downie, W. D. Lyman, and J. W. Berman, “Astrocyte-derived monocyte-chemoattractant protein-1 directs the transmigration of leukocytes across a model of the human blood-brain barrier,” Journal of Immunology, vol. 161, no. 12, pp. 6896–6903, 1998. View at Google Scholar
  50. M. K. Winkler and E. N. Benveniste, “Transforming growth factor-beta inhibition of cytokine-induced vascular cell adhesion molecule-1 expression in human astrocytes,” Glia, vol. 22, no. 2, pp. 171–179, 1998. View at Google Scholar
  51. K. Biernacki, A. Prat, M. Blain, and J. P. Antel, “Regulation of Th1 and Th2 lymphocyte migration by human adult brain endothelial cells,” Journal of Neuropathology and Experimental Neurology, vol. 60, no. 12, pp. 1127–1136, 2001. View at Google Scholar
  52. G. Xi, R. F. Greiser, and F. R. Keep, “The role of thrombin and thrombin receptors in ischemic, haemorrhagic and traumatic brain injury: deleterious or protective,” Journal of Neurochemistry, vol. 84, pp. 3–9, 2003. View at Google Scholar
  53. H. Wang and G. Reiser, “Thrombin signaling in the brain: the role of protease-activated receptors,” Biological Chemistry, vol. 384, no. 2, pp. 193–202, 2003. View at Publisher · View at Google Scholar · View at PubMed
  54. D. Vivien and A. Buisson, “Serine protease inhibitors: novel therapeutic targets for stroke?” Journal of Cerebral Blood Flow and Metabolism, vol. 20, no. 5, pp. 755–764, 2000. View at Google Scholar
  55. R. J. A. Grand, A. S. Turnell, and P. W. Grabham, “Cellular consequences of thrombin-receptor activation,” Biochemical Journal, vol. 313, no. 2, pp. 353–368, 1996. View at Google Scholar
  56. T. Masada, G. Xi, Y. Hua, and R. F. Keep, “The effects of thrombin preconditioning on focal cerebral ischemia in rats,” Brain Research, vol. 867, no. 1-2, pp. 173–179, 2000. View at Publisher · View at Google Scholar
  57. F. Striggow, M. Riek, J. Breder, P. Henrich-Noack, K. G. Reymann, and G. Reiser, “The protease thrombin is an endogenous mediator of hippocampal neuroprotection against ischemia at low concentrations but causes degeneration at high concentrations,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 5, pp. 2264–2269, 2000. View at Publisher · View at Google Scholar · View at PubMed
  58. M. B. Gingrich and S. F. Traynelis, “Serine proteases and brain damage—is there a link?” Trends in Neurosciences, vol. 23, no. 9, pp. 399–407, 2000. View at Publisher · View at Google Scholar
  59. C. Huang, R. Ma, S. Sun, G. Wei, Y. Fang, R. Liu, and G. Li, “JAK2-STAT3 signaling pathway mediates thrombin-induced proinflammatory actions of microglia in vitro,” Journal of Neuroimmunology, vol. 204, no. 1-2, pp. 118–125, 2008. View at Publisher · View at Google Scholar · View at PubMed
  60. J. J. Ubl, M. Sergeeva, and G. Reiser, “Desensitisation of protease-activated receptor-1 (PAR-1) in rat astrocytes: evidence for a novel mechanism for terminating Ca2+ signalling evoked by the tethered ligand,” Journal of Physiology, vol. 525, no. 2, pp. 319–330, 2000. View at Google Scholar
  61. A. Buisson, O. Nicole, F. Docagne, H. Sartelet, E. T. Mackenzie, and D. Vivien, “Up-regulation of a serine protease inhibitor in astrocytes mediates the neuroprotective activity of transforming growth factor β1,” The FASEB Journal, vol. 12, no. 15, pp. 1683–1691, 1998. View at Google Scholar
  62. K. P. Cavanaugh, D. Gurwitz, D. D. Cunningham, and R. A. Bradshaw, “Reciprocal modulation of astrocyte stellation by thrombin and protease nexin-1,” Journal of Neurochemistry, vol. 54, no. 5, pp. 1735–1743, 1990. View at Google Scholar
  63. A. Pindon, D. Hantai, M. Jandrot-Perrus, and B. W. Festoff, “Novel expression and localization of active thrombomodulin on the surface of mouse brain astrocytes,” Glia, vol. 19, no. 3, pp. 259–268, 1997. View at Publisher · View at Google Scholar
  64. K. P. Sarker, H. Ymamhata, M. Nakata, T. Arisato, T. Nakajima, and I. Kitajima, “Recombinant thrombomodulin inhibits thrombin—induced vascular endothelial growth factor production in neuronal cells,” Haemostasis, vol. 29, no. 6, pp. 343–352, 1999. View at Google Scholar
  65. M. M. Bilak, S. P. Becerra, A. M. Vincent, B. H. Moss, M. S. Aymerich, and R. W. Kuncl, “Identification of the neuroprotective molecular region of pigment epithelium-derived factor and its binding sites on motor neurons,” Journal of Neuroscience, vol. 22, no. 21, pp. 9378–9386, 2002. View at Google Scholar
  66. Y. Sugita, S. P. Becerra, G. J. Chader, and J. P. Schwartz, “Pigment epithelium-derived factor (PEDF) has direct effects on the metabolism and proliferation of microglia and indirect effects on astrocytes,” Journal of Neuroscience Research, vol. 49, no. 6, pp. 710–718, 1997. View at Publisher · View at Google Scholar
  67. F. Docagne, O. Nicole, H. H. Marti, E. T. MacKenzie, A. Buisson, and D. Vivien, “Transforming growth factor-β1 as a regulator of the serpins/t-PA axis in cerebral ischemia,” The FASEB Journal, vol. 13, no. 11, pp. 1315–1324, 1999. View at Google Scholar
  68. C. Gabriel, C. Ali, and C. Ali, “Transforming growth factor alpha-induced expression of type 1 plasminogen activator inhibitor in astrocytes rescues neurons from excitotoxicity,” The FASEB Journal, vol. 17, no. 2, pp. 277–279, 2003. View at Google Scholar
  69. M.-C. Hoffmann, C. Nitsch, A. L. Scotti, E. Reinhard, and D. Monard, “The prolonged presence of glia-derived nexin, an endogenous protease inhibitor, in the hippocampus after ischemia-induced delayed neuronal death,” Neuroscience, vol. 49, no. 2, pp. 397–408, 1992. View at Publisher · View at Google Scholar
  70. A. Buisson, S. Lesne, F. Docagne, C. Ali, O. Nicole, E. T. MacKenzie, and D. Vivien, “Transforming growth factor-β and ischemic brain injury,” Cellular and Molecular Neurobiology, vol. 23, no. 4-5, pp. 539–550, 2003. View at Publisher · View at Google Scholar
  71. M. Yepes, M. Sandkvist, M. K. K. Wong, T. A. Coleman, E. Smith, S. L. Cohan, and D. A. Lawrence, “Neuroserpin reduces cerebral infarct volume and protects neurons from ischemia-induced apoptosis,” Blood, vol. 96, no. 2, pp. 569–576, 2000. View at Google Scholar
  72. E. Hansson and L. Rönnbäck, “Glial neuronal signaling in the central nervous system,” The FASEB Journal, vol. 17, no. 3, pp. 341–348, 2003. View at Publisher · View at Google Scholar · View at PubMed
  73. A. Suzumura, M. Sawada, H. Yamamoto, and T. Marunouchi, “Transforming growth factor-β suppresses activation and proliferation of microglia in vitro,” Journal of Immunology, vol. 151, no. 4, pp. 2150–2158, 1993. View at Google Scholar
  74. T. C. Brionne, I. Tesseur, E. Masliah, and T. Wyss-Coray, “Loss of TGF-β1 leads to increased neuronal cell death and microgliosis in mouse brain,” Neuron, vol. 40, no. 6, pp. 1133–1145, 2003. View at Publisher · View at Google Scholar
  75. M. Sawada, A. Suzumura, H. Hosoya, T. Marunouchi, and T. Nagatsu, “Interleukin-10 inhibits both production of cytokines and expression of cytokine receptors in microglia,” Journal of Neurochemistry, vol. 72, no. 4, pp. 1466–1471, 1999. View at Publisher · View at Google Scholar
  76. J. R. R. Heyen, S.-M. Ye, B. N. Finck, and R. W. Johnson, “Interleukin (IL)-10 inhibits IL-6 production in microglia by preventing activation of NF-κB,” Molecular Brain Research, vol. 77, no. 1, pp. 138–147, 2000. View at Publisher · View at Google Scholar
  77. E. Polazzi and A. Contestabile, “Neuron-conditioned media differentially affect the survival of activated or unstimulated microglia: evidence for neuronal control on apoptotic elimination of activated microglia,” Journal of Neuropathology and Experimental Neurology, vol. 62, no. 4, pp. 351–362, 2003. View at Google Scholar
  78. H. H. Majed, S. Chandran, and S. Chandran, “A novel role for Sema3A in neuroprotection from injury mediated by activated microglia,” Journal of Neuroscience, vol. 26, no. 6, pp. 1730–1738, 2006. View at Publisher · View at Google Scholar · View at PubMed
  79. R. T. Mott, G. Ait-Ghezala, and G. Ait-Ghezala, “Neuronal expression of CD22: novel mechanism for inhibiting microglial proinflammatory cytokine production,” Glia, vol. 46, no. 4, pp. 369–379, 2004. View at Publisher · View at Google Scholar · View at PubMed
  80. U. Tontsch and O. Rott, “Cortical neurons selectively inhibit MHC class II induction in astrocytes but not in microglial cells,” International Immunology, vol. 5, no. 3, pp. 249–254, 1993. View at Google Scholar
  81. H. Neumann, J. Boucraut, C. Hahnel, T. Misgeld, and H. Wekerle, “Neuronal control of MHC class II inducibility in rat astrocytes and microglia,” European Journal of Neuroscience, vol. 8, no. 12, pp. 2582–2590, 1996. View at Publisher · View at Google Scholar
  82. J. F. Kerr, A. H. Wyllie, and A. R. Currie, “Apoptosis a basic biological phenomenon with wide ranging implications in tissue kinetics,” International Review of Cytology, vol. 68, pp. 251–306, 1980. View at Google Scholar
  83. L. J. Martin, “Neuronal cell death in nervous system development, disease, and injury,” International Journal of Molecular Medicine, vol. 7, no. 5, pp. 455–478, 2001. View at Google Scholar
  84. R. Hanayama, M. Tanaka, K. Miwa, A. Shinohara, A. Iwamatsu, and S. Nagata, “Identification of a factor that links apoptotic cells to phagocytes,” Nature, vol. 417, no. 6885, pp. 182–187, 2002. View at Publisher · View at Google Scholar · View at PubMed
  85. A. H. Wyllie, J. F. R. Kerr, and A. R. Currie, “Cell death: the significance of apoptosis,” International Review of Cytology, vol. 68, pp. 251–306, 1980. View at Google Scholar · View at Scopus
  86. R. Gold, H.-P. Hartung, and H. Lassmann, “T-cell apoptosis in autoimmune diseases: termination of inflammation in the nervous system and other sites with specialized immune-defense mechanisms,” Trends in Neurosciences, vol. 20, no. 9, pp. 399–404, 1997. View at Publisher · View at Google Scholar
  87. M. P. Pender and M. J. Rist, “Apoptosis of inflammatory cells in immune control of the nervous system: role of glia,” Glia, vol. 36, no. 2, pp. 137–144, 2001. View at Publisher · View at Google Scholar · View at PubMed
  88. P. M. Henson, D. L. Bratton, and V. A. Fadok, “Apoptotic cell removal,” Current Biology, vol. 11, no. 19, pp. R795–R805, 2001. View at Publisher · View at Google Scholar
  89. S. J. Lee, T. Zhou, C. Choi, Z. Wang, and E. N. Benveniste, “Differential regulation and function of Fas expression on glial cells,” Journal of Immunology, vol. 164, no. 3, pp. 1277–1285, 2000. View at Google Scholar
  90. A. Flügel, F. W. Schwaiger, and F. W. Schwaiger, “Neuronal FasL induces cell death of encephalitogenic T lymphocytes,” Brain Pathology, vol. 10, no. 3, pp. 353–364, 2000. View at Google Scholar
  91. P. Saas, J. Boucraut, and J. Boucraut, “CD95 (Fas/Apo-1) as a receptor governing astrocyte apoptotic or inflammatory responses: a key role in brain inflammation?” Journal of Immunology, vol. 162, no. 4, pp. 2326–2333, 1999. View at Google Scholar
  92. U. Felderhoff-Mueser, D. L. Taylor, and D. L. Taylor, “Fas/CD95/APO-1 can function as a death receptor for neuronal cells in vitro and in vivo and is upregulated following cerebral hypoxic-ischemic injury to the developing rat brain,” Brain Pathology, vol. 10, no. 1, pp. 17–29, 2000. View at Google Scholar
  93. C. Choi and E. N. Benveniste, “Fas ligand/Fas system in the brain: regulator of immune and apoptotic responses,” Brain Research Reviews, vol. 44, no. 1, pp. 65–81, 2004. View at Publisher · View at Google Scholar
  94. H.-P. Eugster, K. Frei, R. Bachmann, H. Bluethmann, H. Lassmann, and A. Fontana, “Severity of symptoms and demyelination in MOG-induced EAE depends on TNFR1,” European Journal of Immunology, vol. 29, no. 2, pp. 626–632, 1999. View at Publisher · View at Google Scholar
  95. L. Probert, H.-P. Eugster, K. Akassoglu, J. Bauer, K. Frei, H. Lassmann, and A. Fontana, “TNFR1 signalling is critical for the development of demyelination and the limitation of T-cell responses during immune-mediated CNS disease,” Brain, vol. 123, no. 10, pp. 2005–2019, 2000. View at Google Scholar
  96. K. Akassoglou, J. Bauer, G. Kassiotis, M. Pasparakis, H. Lassmann, G. Kollias, and L. Probert, “Oligodendrocyte apoptosis and primary demyelination induced by local TNF/p55TNF receptor signaling in the central nervous system of transgenic mice: models for multiple sclerosis with primary oligodendrogliopathy,” American Journal of Pathology, vol. 153, no. 3, pp. 801–813, 1998. View at Google Scholar
  97. O. Aktas, U. Schulze-Topphoff, and F. Zipp, “The role of TRAIL/TRAIL receptors in central nervous system pathology,” Frontiers in Bioscience, vol. 12, pp. 2912–2921, 2007. View at Publisher · View at Google Scholar
  98. T. Magnus, A. Chan, O. Grauer, K. V. Toyka, and R. Gold, “Microglial phagocytosis of apoptotic inflammatory T cells leads to down-regulation of microglial immune activation,” Journal of Immunology, vol. 167, no. 9, pp. 5004–5010, 2001. View at Google Scholar
  99. R. E. Voll, M. Herrmann, E. A. Roth, C. Stach, J. R. Kalden, and I. Girkontaite, “Immunosuppressive effects of apoptotic cells,” Nature, vol. 390, no. 6658, pp. 350–351, 1997. View at Publisher · View at Google Scholar · View at PubMed
  100. C. G. Freire-de-Lima, Y. Q. Xiao, S. J. Gardai, D. L. Bratton, W. P. Schiemann, and P. M. Henson, “Apoptotic cells, through transforming growth factor-β, coordinately induce anti-inflammatory and suppress pro-inflammatory eicosanoid and NO synthesis in murine macrophages,” Journal of Biological Chemistry, vol. 281, no. 50, pp. 38376–38384, 2006. View at Publisher · View at Google Scholar · View at PubMed
  101. V. A. Fadok, D. L. Bratton, A. Konowal, P. W. Freed, J. Y. Westcott, and P. M. Henson, “Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-β, PGE2, and PAF,” Journal of Clinical Investigation, vol. 101, no. 4, pp. 890–898, 1998. View at Google Scholar
  102. M.-L. N. Huynh, V. A. Fadok, and P. M. Henson, “Phosphatidylserine-dependent ingestion of apoptotic cells promotes TGF-β1 secretion and the resolution of inflammation,” Journal of Clinical Investigation, vol. 109, no. 1, pp. 41–50, 2002. View at Publisher · View at Google Scholar
  103. H. A. Golpon, V. A. Fadok, and V. A. Fadok, “Life after corpse engulfment: phagocytosis of apoptotic cells leads to VEGF secretion and cell growth,” The FASEB Journal, vol. 18, no. 14, pp. 1716–1718, 2004. View at Publisher · View at Google Scholar · View at PubMed
  104. V. A. Fadok and G. Chimini, “The phagocytosis of apoptotic cells,” Seminars in Immunology, vol. 13, no. 6, pp. 365–372, 2001. View at Publisher · View at Google Scholar · View at PubMed
  105. J. Savill, I. Dransfield, N. Hogg, and C. Haslett, “Vitronectin receptor-mediated phagocytosis of cells undergoing apoptosis,” Nature, vol. 343, no. 6254, pp. 170–173, 1990. View at Publisher · View at Google Scholar · View at PubMed
  106. V. A. Fadok, M. L. Warner, D. L. Bratton, and P. M. Henson, “CD36 is required for phagocytosis of apoptotic cells by human macrophages that use either a phosphatidylserine receptor or the vitronectin receptor (alpha v beta 3),” Journal of Immunology, vol. 161, no. 11, pp. 6250–6257, 1998. View at Google Scholar
  107. Y. Liu, S. Walter, and S. Walter, “LPS receptor (CD14): a receptor for phagocytosis of Alzheimer's amyloid peptide,” Brain, vol. 128, no. 8, pp. 1778–1789, 2005. View at Publisher · View at Google Scholar · View at PubMed
  108. F. Leonardi-Essmann, M. Emig, Y. Kitamura, R. Spanagel, and P. J. Gebicke-Haerter, “Fractalkine-upregulated milk-fat globule EGF factor-8 protein in cultured rat microglia,” Journal of Neuroimmunology, vol. 160, no. 1-2, pp. 92–101, 2005. View at Publisher · View at Google Scholar · View at PubMed
  109. P. R. Hoffmann, A. M. deCathelineau, and A. M. deCathelineau, “Phosphatidylserine (PS) induces PS receptor-mediated macropinocytosis and promotes clearance of apoptotic cells,” Journal of Cell Biology, vol. 155, no. 3, pp. 649–660, 2001. View at Google Scholar
  110. M.-K. Chang, C. J. Binder, M. Torzewski et al., “Monoclonal antibodies against oxidised low density lipoprotein bind to apoptotic cells and inhibit their phagocytosis by elicited macrophages ;evidence that oxidation -specific epitopes mediate macrophage recognition,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, pp. 6353–6358, 1999. View at Google Scholar
  111. R. De Simone, M. A. Ajmone-Cat, and L. Minghetti, “Atypical antiinflammatory activation of microglia induced by apoptotic neurons: possible role of phosphatidylserine-phosphatidylserine receptor interaction,” Molecular Neurobiology, vol. 29, no. 2, pp. 197–212, 2004. View at Publisher · View at Google Scholar · View at PubMed
  112. P. R. Taylor, A. Carugati, and A. Carugati, “A hierarchical role for classical pathway complement proteins in the clearance of apoptotic cells in vivo,” Journal of Experimental Medicine, vol. 192, no. 3, pp. 359–366, 2000. View at Publisher · View at Google Scholar
  113. A. J. Nauta, L. A. Trouw, and L. A. Trouw, “Direct binding of C1q to apoptotic cells and cell blebs induces complement activation,” European Journal of Immunology, vol. 32, no. 6, pp. 1726–1736, 2002. View at Google Scholar
  114. M. R. W. Ehlers, “CR3: a general purpose adhesion-recognition receptor essential for innate immunity,” Microbes and Infection, vol. 2, no. 3, pp. 289–294, 2000. View at Publisher · View at Google Scholar
  115. G. D. Ross, “Role of the lectin domain of Mac-1/CR3 (CD11b/CD18) in regulating intercellular adhesion,” Immunologic Research, vol. 25, no. 3, pp. 219–227, 2002. View at Publisher · View at Google Scholar · View at PubMed
  116. H. Gerwuz and S. C. Yiang, “Non immune activation of the classical complement pathway,” Behring Institute Mitteilungen, vol. 93, pp. 138–147, 1993. View at Google Scholar
  117. L. C. Korb and J. M. Ahearn, “C1q binds directly and specifically to surface blebs of apoptotic human keratinocytes: complement deficiency and systemic lupus erythematosus revisited,” Journal of Immunology, vol. 158, no. 10, pp. 4525–4528, 1997. View at Google Scholar
  118. S. K. Singhrao, J. W. Neal, N. K. Rushmere, B. P. Morgan, and P. Gasque, “Differential expression of individual complement regulators in the brain and choroid plexus,” Laboratory Investigation, vol. 79, no. 10, pp. 1247–1259, 1999. View at Google Scholar
  119. B. P. Morgan and C. E. Harris., Regulation in the Terminal Pathway Membrane Regulators of the Terminal Pathway Complement Regulatory Proteins, Academic Press, San Diego, Calif, USA, 1999.
  120. S. K. Singhrao, J. W. Neal, N. K. Rushmere, B. P. Morgan, and P. Gasque, “Spontaneous classical pathway activation and deficiency of membrane regulators render human neurons susceptible to complement lysis,” American Journal of Pathology, vol. 157, no. 3, pp. 905–918, 2000. View at Google Scholar
  121. J. Van Beek, M. Van Meurs, and M. Van Meurs, “Decay-accelerating factor (CD55) is expressed by neurons in response to chronic but not acute autoimmune central nervous system inflammation associated with complement activation,” Journal of Immunology, vol. 174, no. 4, pp. 2353–2365, 2005. View at Google Scholar
  122. J. Van Beek, O. Nicole, C. Ali, A. Ischenko, E. T. MacKenzie, A. Buisson, and M. Fontaine, “Complement anaphylatoxin C3a is selectively protective against NMDA-induced neuronal cell death,” Neuroreport, vol. 12, no. 2, pp. 289–293, 2001. View at Google Scholar
  123. Y. Rahpeymai, M. A. Hietala, and M. A. Hietala, “Complement: a novel factor in basal and ischemia-induced neurogenesis,” The EMBO Journal, vol. 25, no. 6, pp. 1364–1374, 2006. View at Publisher · View at Google Scholar · View at PubMed
  124. I. U. Schraufstatter, R. G. DiScipio, M. Zhao, and S. K. Khaldoyanidi, “C3a and C5a are chemotactic factors for human mesenchymal stem cells, which cause prolonged ERK1/2 phosphorylation,” Journal of Immunology, vol. 182, no. 6, pp. 3827–3836, 2009. View at Publisher · View at Google Scholar · View at PubMed
  125. S. Meri, P. Mattila, and R. Renkonen, “Regulation of CD59 expression on the human endothelial cell line EA.hy 926,” European Journal of Immunology, vol. 23, no. 10, pp. 2511–2516, 1993. View at Google Scholar
  126. C. Yang, J. L. Jones, and S. R. Barnum, “Expression of decay-accelerating factor (CD55), membrane cofactor protein (CD46) and CD59 in the human astroglioma cell line, D54-MG, and primary rat astrocytes,” Journal of Neuroimmunology, vol. 47, no. 2, pp. 123–132, 1993. View at Publisher · View at Google Scholar
  127. S. R. Barnum, “Complement in central nervous system inflammation,” Immunologic Research, vol. 26, no. 1–3, pp. 7–13, 2002. View at Google Scholar
  128. M. R. Griffiths, J. W. Neal, M. Fontaine, T. Das, and P. Gasque, “Complement factor H, a marker of self protects against experimental autoimmune encephalomyelitis,” Journal of Immunology, vol. 182, no. 7, pp. 4368–4377, 2009. View at Publisher · View at Google Scholar · View at PubMed
  129. R. J. Meade, J. W. Neal, M. R. Griffiths et al., “Deficiency of complement regulator CD59a enhances disease severity, demeylination and axonal injury in murine acute allergic encephalomyelitis,” Laboratory Investigation, vol. 84, pp. 21–28, 2004. View at Google Scholar
  130. P. Gasque, M. Fontaine, and B. P. Morgan, “Complement expression in human brain: biosynthesis of terminal pathway components and regulators in human glial cells and cell lines,” Journal of Immunology, vol. 154, no. 9, pp. 4726–4733, 1995. View at Google Scholar
  131. P. Gasque, A. Thomas, M. Fontaine, and B. P. Morgan, “Complement activation on human neuroblastoma cell lines in vitro: route of activation and expression of functional complement regulatory proteins,” Journal of Neuroimmunology, vol. 66, no. 1-2, pp. 29–40, 1996. View at Publisher · View at Google Scholar
  132. D. G. Walker, S. U. Kim, and P. L. McGeer, “Complement and cytokine gene expression in cultured microglia derived from postmortem human brains,” Journal of Neuroscience Research, vol. 40, no. 4, pp. 478–493, 1995. View at Publisher · View at Google Scholar · View at PubMed
  133. A. Kojima, K. Iwata, T. Seya, M. Matsumoto, H. Ariga, J. P. Atkinson, and S. Nagasawa, “Membrane cofactor protein (CD46) protects cells predominantly from alternative complement pathway-mediated C3-fragment deposition and cytolysis,” Journal of Immunology, vol. 151, no. 3, pp. 1519–1527, 1993. View at Google Scholar
  134. A. Moutabarrik, I. Nakanishi, and I. Nakanishi, “Cytokine-mediated regulation of the surface expression of complement regulatory proteins, CD46(MCP), CD55(DAF), and CD59 on human vascular endothelial cells,” Lymphokine and Cytokine Research, vol. 12, no. 3, pp. 167–172, 1993. View at Google Scholar
  135. G. M. Pasinetti, S. A. Johnson, T. Oda, I. Rozovsky, and C. A. Finch, “Clusterin (SGP_2): a multi functional glycoprotein with regional expression in astrocytes and neurons of the adult rat brain,” Journal of Comparative Neurology, vol. 339, pp. 387–400, 1994. View at Google Scholar
  136. P. Gasque and B. P. Morgan, “Complement regulatory protein expression by a human oligodendrocyte cell line: cytokine regulation and comparison with astrocytes,” Immunology, vol. 89, no. 3, pp. 338–347, 1996. View at Google Scholar
  137. J. Zajicek, M. Wing, J. Skepper, and A. Compston, “Human oligodendrocytes are not sensitive to complement: a study of CD59 expression in the human central nervous system,” Laboratory Investigation, vol. 73, no. 1, pp. 128–138, 1995. View at Google Scholar
  138. K.-Z. Zhang, S. Junnikkala, M. G. Erlander, H. Guo, J. A. Westberg, S. Meri, and L. C. Andersson, “Up-regulated expression of decay-accelerating factor (CD55) confers increased complement resistance to sprouting neural cells,” European Journal of Immunology, vol. 28, no. 4, pp. 1189–1196, 1998. View at Publisher · View at Google Scholar
  139. B. Sivasankar, R. M. Donev, and R. M. Donev, “CD59a deficient mice display reduced B cell activity and antibody production in response to T-dependent antigens,” Molecular Immunology, vol. 44, no. 11, pp. 2978–2987, 2007. View at Google Scholar
  140. J. Liu, T. Miwa, B. Hilliard, Y. Chen, J. D. Lambris, A. D. Wells, and W.-C. Song, “The complement inhibitory protein DAF (CD55) suppresses T cell immunity in vivo,” Journal of Experimental Medicine, vol. 201, no. 4, pp. 567–577, 2005. View at Publisher · View at Google Scholar · View at PubMed
  141. M. P. Longhi, B. Sivasankar, N. Omidvar, B. P. Morgan, and A. Gallimore, “Cutting edge: murine CD59a modulates antiviral CD4+ T cell activity in a complement-independent manner,” Journal of Immunology, vol. 175, no. 11, pp. 7098–7102, 2005. View at Google Scholar
  142. M. P. Longhi, C. L. Harris, B. P. Morgan, and A. Gallimore, “Holding T cells in check—a new role for complement regulators?” Trends in Immunology, vol. 27, no. 2, pp. 102–108, 2006. View at Publisher · View at Google Scholar · View at PubMed
  143. A. Cerwenka and L. L. Lanier, “Natural killer cells, viruses and cancer,” Nature Reviews Immunology, vol. 1, no. 1, pp. 41–49, 2001. View at Google Scholar
  144. K. Elward, M. Griffiths, M. Mizuno, C. L. Harris, J. W. Neal, B. P. Morgan, and P. Gasque, “CD46 plays a key role in tailoring innate immune recognition of apoptotic and necrotic cells,” Journal of Biological Chemistry, vol. 280, no. 43, pp. 36342–36354, 2005. View at Publisher · View at Google Scholar · View at PubMed
  145. C. Jones, M. Virji, and P. R. Crocker, “Recognition of sialylated meningococcal lipopolysaccharide by siglecs expressed on myeloid cells leads to enhanced bacterial uptake,” Molecular Microbiology, vol. 49, no. 5, pp. 1213–1225, 2003. View at Publisher · View at Google Scholar
  146. P. R. Crocker and A. Varki, “Siglecs, sialic acids and innate immunity,” Trends in Immunology, vol. 22, no. 6, pp. 337–342, 2001. View at Publisher · View at Google Scholar
  147. C. Broderick, R. M. Hoek, J. V. Forrester, J. Liversidge, J. D. Sedgwick, and A. D. Dick, “Constitutive retinal CD200 expression regulates resident microglia and activation state of inflammatory cells during experimental autoimmune uveoretinitis,” American Journal of Pathology, vol. 161, no. 5, pp. 1669–1677, 2002. View at Google Scholar
  148. N. Koning, D. F. Swaab, R. M. Hoek, and I. Huitinga, “Distribution of the immune inhibitory molecules CD200 and CD200R in the normal central nervous system and multiple sclerosis lesions suggests neuron-glia and glia-glia interactions,” Journal of Neuropathology and Experimental Neurology, vol. 68, no. 2, pp. 159–167, 2009. View at Publisher · View at Google Scholar · View at PubMed
  149. M. D. Rosenblum, E. Olasz, and E. Olasz, “CD200 is a novel p53-target gene involved in apoptosis-associated immune tolerance,” Blood, vol. 103, no. 7, pp. 2691–2698, 2004. View at Publisher · View at Google Scholar · View at PubMed
  150. G. J. Wright, M. Jones, M. J. Puklavec, M. H. Brown, and A. N. Barclay, “The unusual distribution of the neuronal/lymphoid cell surface CD200 (OX2) glycoprotein is conserved in humans,” Immunology, vol. 102, no. 2, pp. 173–179, 2001. View at Publisher · View at Google Scholar
  151. M. I. Reinhold, F. P. Lindberg, D. Plas, S. Reynolds, M. G. Peters, and E. J. Brown, “In vivo expression of alternatively spliced forms of integrin-associated protein (CD47),” Journal of Cell Science, vol. 108, no. 11, pp. 3419–3425, 1995. View at Google Scholar
  152. S. Latour, H. Tanaka, and H. Tanaka, “Bidirectional negative regulation of human T and dendritic cells by CD47 and its cognate receptor signal regulator protein-alpha: down regulation of IL-12 responsiveness and inhibition of dendritic cell activation,” Journal of Immunology, vol. 167, no. 5, pp. 2547–2554, 2001. View at Google Scholar
  153. L. Lamy, A. Foussat, E. J. Brown, P. Bornstein, M. Ticchioni, and A. Bernard, “Interactions between CD47 and thrombospondin reduce inflammation,” Journal of Immunology, vol. 178, no. 9, pp. 5930–5939, 2007. View at Google Scholar
  154. P. Oldenborg, H. D. Gresham, and F. D. Lindberg, “CD47-signal regulatory protein alpha (SIRPalpha) regulates Fc gamma and complement receptor-mediated phagocytosis,” Journal of Experimental Medicine, vol. 193, pp. 855–862, 2001. View at Google Scholar
  155. P. P. Manna, J. Dimitry, P.-A. Oldenborg, and W. A. Frazier, “CD47 augments fas/CD95-mediated apoptosis,” Journal of Biological Chemistry, vol. 280, no. 33, pp. 29637–29644, 2005. View at Publisher · View at Google Scholar · View at PubMed
  156. S. Pluchino and G. Martino, “Neural stem cell-mediated immunomodulation: repairing the haemorrhagic brain,” Brain, vol. 131, no. 3, pp. 604–605, 2008. View at Publisher · View at Google Scholar · View at PubMed
  157. J. Ourednik, V. Ourednik, W. P. Lynch, M. Schachner, and E. Y. Snyder, “Neural stem cells display an inherent mechanism for rescuing dysfunctional neurons,” Nature Biotechnology, vol. 20, no. 11, pp. 1103–1110, 2002. View at Publisher · View at Google Scholar · View at PubMed
  158. P. Lu, L. L. Jones, E. Y. Snyder, and M. H. Tuszynski, “Neural stem cells constitutively secrete neurotrophic factors and promote extensive host axonal growth after spinal cord injury,” Experimental Neurology, vol. 181, no. 2, pp. 115–129, 2003. View at Publisher · View at Google Scholar
  159. G. Martino and S. Pluchino, “The therapeutic potential of neural stem cells,” Nature Reviews Neuroscience, vol. 7, no. 5, pp. 395–406, 2006. View at Publisher · View at Google Scholar · View at PubMed
  160. S. Pluchino, L. Zanotti, and L. Zanotti, “Neurosphere-derived multipotent precursors promote neuroprotection by an immunomodulatory mechanism,” Nature, vol. 436, no. 7048, pp. 266–271, 2005. View at Publisher · View at Google Scholar · View at PubMed
  161. C. Zhao, W. Deng, and F. H. Gage, “Mechanisms and functional implications of adult neurogenesis,” Cell, vol. 132, no. 4, pp. 645–660, 2008. View at Publisher · View at Google Scholar · View at PubMed
  162. A. Alvarez-Buylla and D. A. Lim, “For the long run: maintaining germinal niches in the adult brain,” Neuron, vol. 41, no. 5, pp. 683–686, 2004. View at Publisher · View at Google Scholar
  163. J. Imitola, M. Comabella, A. K. Chandraker, F. Dangond, M. H. Sayegh, E. Y. Snyder, and S. J. Khoury, “Neural stem/progenitor cells express costimulatory molecules that are differentially regulated by inflammatory and apoptotic stimuli,” American Journal of Pathology, vol. 164, no. 5, pp. 1615–1625, 2004. View at Google Scholar
  164. G. Moalem, A. Gdalyahu, Y. Shani, U. Otten, P. Lazarovici, I. R. Cohen, and M. Schwartz, “Production of neurotrophins by activated T cells: implications for neuroprotective autoimmunity,” Journal of Autoimmunity, vol. 15, no. 3, pp. 331–345, 2000. View at Publisher · View at Google Scholar · View at PubMed
  165. J. Kipnis, T. Mizrahi, E. Hauben, I. Shaked, E. Shevach, and M. Schwartz, “Neuroprotective autoimmunity: naturally occurring CD4+CD25+ regulatory T cells suppress the ability to withstand injury to the central nervous system,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 24, pp. 15620–15625, 2002. View at Publisher · View at Google Scholar · View at PubMed
  166. F. Powrie and K. J. Maloy, “Immunology: regulating the regulators,” Science, vol. 299, no. 5609, pp. 1030–1031, 2003. View at Publisher · View at Google Scholar · View at PubMed
  167. M. Kerschensteiner, E. Gallmeier, and E. Gallmeier, “Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation?” Journal of Experimental Medicine, vol. 189, no. 5, pp. 865–870, 1999. View at Publisher · View at Google Scholar
  168. M. Kerschensteiner, C. Stadelmann, G. Dechant, H. Wekerle, and R. Hohlfeld, “Neurotrophic cross-talk between the nervous and immune systems: implications for neurological diseases,” Annals of Neurology, vol. 53, no. 3, pp. 292–304, 2003. View at Publisher · View at Google Scholar · View at PubMed
  169. C. Stadelmann, M. Kerschensteiner, T. Misgeld, W. Brück, R. Hohlfeld, and H. Lassmann, “BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells?” Brain, vol. 125, no. 1, pp. 75–85, 2002. View at Google Scholar
  170. H. Hammarberg, O. Lidman, and O. Lidman, “Neuroprotection by encephalomyelitis: rescue of mechanically injured neurons and neurotrophin production by CNS-infiltrating T and natural killer cells,” Journal of Neuroscience, vol. 20, no. 14, pp. 5283–5291, 2000. View at Google Scholar
  171. E. Polazzi, L. E. P. Altamira, S. Eleuteri, R. Barbaro, C. Casadio, A. Contestabile, and B. Monti, “Neuroprotection of microglial conditioned medium on 6-hydroxydopamine- induced neuronal death: role of transforming growth factor beta-2,” Journal of Neurochemistry, vol. 110, no. 2, pp. 545–556, 2009. View at Publisher · View at Google Scholar · View at PubMed
  172. M. Aharonowiz, O. Einstein, N. Fainstein, H. Lassmann, B. Reubinoff, and T. Ben-Hur, “Neuroprotective effect of transplanted human embryonic stem cell-derived neural precursors in an animal model of multiple sclerosis,” PLoS One, vol. 3, no. 9, article e3145, 2008. View at Publisher · View at Google Scholar · View at PubMed
  173. E. Gonzalez-Rey, M. A. Gonzalez, N. Varela et al., “Human adipose-derived mesenchymal stem cells reduce inflammatory and T cell responses and induce regulatory T cells in vitro in rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 69, no. 1, pp. 241–248, 2010. View at Publisher · View at Google Scholar · View at PubMed
  174. K. Sato, K. Ozaki, I. Oh et al., “Nitiric oxide plays a critical role in suppression of T-cell proliferation by mesenchyal stem cells,” Blood, vol. 109, pp. 228–234, 2007. View at Google Scholar
  175. G. Ren, L. Zhang, and L. Zhang, “Mesenchymal stem cell mediated immunosuppression occurs via a concerted action of chemokines and nitric oxide,” Cell Stem Cell, vol. 2, no. 2, pp. 141–150, 2008. View at Publisher · View at Google Scholar · View at PubMed
  176. J.-A. Kim, S. Hong, B. Lee, J. W. Hong, J.-Y. Kwak, S. Cho, and C.-C. Kim, “The inhibition of T-cells proliferation by mouse mesenchymal stem cells through the induction of p16INK4A-cyclin D1/cdk4 and p21waf1, p27kip1-cyclin E/cdk2 pathways,” Cellular Immunology, vol. 245, no. 1, pp. 16–23, 2007. View at Publisher · View at Google Scholar · View at PubMed
  177. B. T. Kawasaki, T. Mistree, E. M. Hurt, M. Kalathur, and W. L. Farrar, “Co-expression of the toleragenic glycoprotein, CD200, with markers for cancer stem cells,” Biochemical and Biophysical Research Communications, vol. 364, no. 4, pp. 778–782, 2007. View at Publisher · View at Google Scholar · View at PubMed
  178. S. J. Morrison and A. C. Spradling, “Stem cells and niches: mechanisms that promote stem cell maintenance throughout life,” Cell, vol. 132, no. 4, pp. 598–611, 2008. View at Publisher · View at Google Scholar · View at PubMed
  179. E. D. Laywell, P. Rakic, V. G. Kukekov, E. C. Holland, and D. A. Steindler, “Identification of a multipotent astrocytic stem cell in the immature and adult mouse brain,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 25, pp. 13883–13888, 2000. View at Publisher · View at Google Scholar · View at PubMed
  180. F. Doetsch, J. M. García-Verdugo, and A. Alvarez-Buylla, “Cellular composition and three-dimensional organization of the subventricular germinal zone in the adult mammalian brain,” Journal of Neuroscience, vol. 17, no. 13, pp. 5046–5061, 1997. View at Google Scholar
  181. D. A. Lim, A. D. Tramontin, J. M. Trevejo, D. G. Herrera, J. M. García-Verdugo, and A. Alvarez-Buylla, “Noggin antagonizes BMP signaling to create a niche for adult neurogenesis,” Neuron, vol. 28, no. 3, pp. 713–726, 2000. View at Publisher · View at Google Scholar
  182. R. Reca, D. Mastellos, and D. Mastellos, “Functional receptor for C3a anaphylatoxin is expressed by normal hematopoietic stem/progenitor cells, and C3a enhances their homing-related responses to SDF-1,” Blood, vol. 101, no. 10, pp. 3784–3793, 2003. View at Publisher · View at Google Scholar · View at PubMed
  183. M. Kucia, R. Reca, and R. Reca, “Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis,” Stem Cells, vol. 23, no. 7, pp. 879–894, 2005. View at Publisher · View at Google Scholar · View at PubMed
  184. J. D. Abbott, Y. Huang, D. Liu, R. Hickey, D. S. Krause, and F. J. Giordano, “Stromal cell derived factor -1alpha plays a critical role in stem cell recruitment to the heart after myocardial infarction but is not sufficient to induce homing tin the absence of injury,” Circulation, vol. 110, no. 21, pp. 3300–3305, 2004. View at Google Scholar
  185. W. D. Hill, D. C. Hess, and D. C. Hess, “SDF-1 (CXCL12) is upregulated in the ischemic penumbra following stroke: association with bone marrow cell homing to injury,” Journal of Neuropathology and Experimental Neurology, vol. 63, no. 1, pp. 84–96, 2004. View at Google Scholar
  186. N. Wright, T. L. De Lera, C. García-Moruja, R. Lillo, F. García-Sánchez, A. Caruz, and J. Teixidó, “Transforming growth factor-β1 down-regulates expression of chemokine stromal cell-derived factor-1: functional consequences in cell migration and adhesion,” Blood, vol. 102, no. 6, pp. 1978–1984, 2003. View at Publisher · View at Google Scholar · View at PubMed
  187. M. Z. Ratajczak, R. Reca, M. Wysoczynski, J. Yan, and J. Ratajczak, “Modulation of the SDF-1-CXCR4 axis by the third complement component (C3)-Implications for trafficking of CXCR4+ stem cells,” Experimental Hematology, vol. 34, no. 8, pp. 986–995, 2006. View at Publisher · View at Google Scholar · View at PubMed
  188. K.-Z. Zhang, S. Junnikkala, M. G. Erlander, H. Guo, J. A. Westberg, S. Meri, and L. C. Andersson, “Up-regulated expression of decay-accelerating factor (CD55) confers increased complement resistance to sprouting neural cells,” European Journal of Immunology, vol. 28, no. 4, pp. 1189–1196, 1998. View at Publisher · View at Google Scholar
  189. P. H. M. Wang, T. T. Schwindt, G. F. Barnabé et al., “Administration of neural precursor cells ameliorates renal ischemia-reperfusion injury,” Nephron Experimental Nephrology, vol. 112, no. 1, pp. e20–e28, 2009. View at Publisher · View at Google Scholar · View at PubMed
  190. O. Einstein, N. Grigoriadis, and N. Grigoriadis, “Transplanted neural precursor cells reduce brain inflammation to attenuate chronic experimental autoimmune encephalomyelitis,” Experimental Neurology, vol. 198, no. 2, pp. 275–284, 2006. View at Publisher · View at Google Scholar · View at PubMed
  191. O. Einstein, N. Fainstein, and N. Fainstein, “Neural precursors attenuate autoimmune encephalomyelitis by peripheral immunosuppression,” Annals of Neurology, vol. 61, no. 3, pp. 209–218, 2007. View at Publisher · View at Google Scholar · View at PubMed
  192. I. Kassis, N. Grigoriadis, and N. Grigoriadis, “Neuroprotection and immunomodulation with mesenchymal stem cells in chronic experimental autoimmune encephalomyelitis,” Archives of Neurology, vol. 65, no. 6, pp. 753–761, 2008. View at Publisher · View at Google Scholar · View at PubMed
  193. S.-Y. Kim, H.-S. Cho, and H.-S. Cho, “Soluble mediators from human neural stem cells play a critical role in suppression of T-cell activation and proliferation,” Journal of Neuroscience Research, vol. 87, no. 10, pp. 2264–2272, 2009. View at Publisher · View at Google Scholar · View at PubMed
  194. W. F. Hickey and H. Kimura, “Perivascular microglial cells of the CNS are bone marrow-derived and present antigen in vivo,” Science, vol. 239, no. 4837, pp. 290–292, 1988. View at Google Scholar
  195. M. Djukic, A. Mildner, and A. Mildner, “Circulating monocytes engraft in the brain, differentiate into microglia and contribute to the pathology following meningitis in mice,” Brain, vol. 129, no. 9, pp. 2394–2403, 2006. View at Publisher · View at Google Scholar · View at PubMed
  196. N. J. Robertson, F. A. Brook, R. L. Gardner, S. P. Cobbold, H. Waldmann, and P. J. Fairchild, “Embryonic stem cell-derived tissues are immunogenic but their inherent immune privilege promotes the induction of tolerance,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 52, pp. 20920–20925, 2007. View at Publisher · View at Google Scholar · View at PubMed
  197. A. Setzu, J. D. Lathia, C. Zhao, K. Wells, M. S. Rao, C. Ffrench-Constant, and R. J. M. Franklin, “Inflammation stimulates myelination by transplanted oligodendrocyte precursor cells,” Glia, vol. 54, no. 4, pp. 297–303, 2006. View at Publisher · View at Google Scholar · View at PubMed
  198. I. Glezer, A. Lapointe, and S. Rivest, “Innate immunity triggers oligodendrocyte progenitor reactivity and confines damages to brain injuries,” The FASEB Journal, vol. 20, no. 6, pp. 750–752, 2006. View at Publisher · View at Google Scholar · View at PubMed